title: Relevance of c-erbB2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer.
abstract: The positivity rates of mRNA expression in breast cancer of the tumor-related genes for c-erbB2, PLU-1 and survivin are unclear. We quantitatively analyzed tissue samples from 39 breast cancers and non-cancerous parts of the same specimens for the above three mRNAs using a TaqMan reverse transcription-polymerase chain reaction (RT-PCR). Using the mean + 2SD of non-cancerous sample as a cut-off value, the positivity rates of the tumors for c-erbB2, PLU-1 and survivin were 20.5%, 7.7% and 69.2%, respectively. Combining consideration of survivin with c-erbB2 and or PLU-1 increased the positivity ratio (survivin plus either of others, 76.9%; survivin plus both, 79.5%). Analysis by histological type indicated that survivin showed the highest positivity in ductal carcinoma and that survivin and PLU-1 showed the same positivity rate (40.0%) in the five carcinomas classified histologically as either solid-tubular or mucinous. Further, all cases that were positive for PLU-1 were negative for survivin. Survivin mRNA expression appeared more useful as a marker for diagnosis of breast cancer than c-erbB2 or PLU-1. However, PLU-1 appeared to vary independently of survivin, enhancing the usefulness of assays considering both in combination.
authors.affiliation: Division of Laboratory Diagnosis, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo 060-8543, Japan.
authors.forename: Akiko
authors.initials: A
authors.lastname: Izawa
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kobayashi
authors.forename: Shunichi
authors.initials: S
authors.lastname: Nasu
authors.forename: Kaori
authors.initials: K
authors.lastname: Saito
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Moriai
authors.forename: Koichi
authors.initials: K
authors.lastname: Asanuma
authors.forename: Masashi
authors.initials: M
authors.lastname: Nakamura
authors.forename: Atsuhito
authors.initials: A
authors.lastname: Yagihashi
authors.forename: Naoki
authors.initials: N
authors.lastname: Watanabe
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000235:genetics*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D004268:DNA-Binding Proteins / Q000096:biosynthesis / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D056484:Jumonji Domain-Containing Histone Demethylases; D008869:Microtubule-Associated Proteins / Q000096:biosynthesis / Q000235:genetics*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics*; D009687:Nuclear Proteins; D012333:RNA, Messenger / Q000096:biosynthesis* / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics*; D012097:Repressor Proteins; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077022:Survivin
chemical_list: D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D051034:Inhibitor of Apoptosis Proteins; D056484:Jumonji Domain-Containing Histone Demethylases; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D012333:RNA, Messenger; D018719:Erb-b2 Receptor Tyrosine Kinases; D012097:Repressor Proteins; D000077022:Survivin; C107489:BIRC5 protein, human; C119611:KDM5B protein, human